Latigo reports Q3 2026 results, names new CEO, adds opioid arm to Phase 3 trialNov 5Quarterly updateCollegium Pharmaceutical, IncLatigo Biotherapeutics
Indivior reports record SUBLOCADE revenue ahead of Supernus merger closeOct 29Quarterly updatebuprenorphineIndivior Pharmaceuticals, Inc.
Amneal clears five FDA supplements: REMS update on buprenorphine/naloxone leads weekAug 14Weekly roundup, 5 itemsAmneal Pharmaceuticals, LLCbuprenorphine
FDA clears five ANDA supplements for Teva and Actavis Labs generics, mostly labeling updatesAug 14Weekly roundup, 5 itemsTeva Pharmaceutical Industries Ltd
Sun Pharma logs eleven FDA labeling supplements and two REMS updates in one weekAug 14Weekly roundup, 11 itemsisotretinoinSun Pharmaceutical Industries
Indivior raises 2026 guidance on record SUBLOCADE revenueAug 3Quarterly updatebuprenorphineIndivior Pharmaceuticals, Inc.